Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
14.13B
Market cap14.13B
Price-Earnings ratio
30.41
Price-Earnings ratio30.41
Dividend yield
Dividend yield
Average volume
2.96M
Average volume2.96M
High today
$102.00
High today$102.00
Low today
$99.41
Low today$99.41
Open price
$102.00
Open price$102.00
Volume
1.98M
Volume1.98M
52 Week high
$104.78
52 Week high$104.78
52 Week low
$61.23
52 Week low$61.23

Stock Snapshot

Halozyme Therapeutics(HALO) stock is priced at $100.67, giving the company a market capitalization of 14.13B. It carries a P/E multiple of 30.41.

On 2026-08-14, Halozyme Therapeutics(HALO) stock moved within a range of $99.41 to $102.00. With shares now at $100.67, the stock is trading +1.3% above its intraday low and -1.3% below the session's peak.

Trading activity shows a volume of 1.98M, compared to an average daily volume of 2.96M.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $104.78 and a low of $61.23.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $104.78 and a low of $61.23.

HALO News

The Motley Fool 13h
Halozyme Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Tram Bui President and Chief Exe...

Halozyme Q2 2026 Earnings Call Transcript
Investing.com 2d
Halozyme director Connaughton sells $167,152 in shares - Investing.com

...

Halozyme director Connaughton sells $167,152 in shares - Investing.com
Simply Wall St 3d
What Halozyme Therapeutics Guidance Raise Means For Valuation

Advertisement Earnings, guidance and new deals put Halozyme Therapeutics in focus Halozyme Therapeutics (HALO) drew fresh attention after reporting second qua...

What Halozyme Therapeutics Guidance Raise Means For Valuation

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

More HALO News

Simply Wall St 5d
Halozyme Therapeutics Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed?

In early August 2026, Halozyme Therapeutics reported record second-quarter results, with revenue rising to US$481 million and net income reaching US$229.91 mill...

Halozyme Therapeutics Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed?
Simply Wall St 7d
Halozyme Therapeutics Stock Looks Expensive At Today’s Price

Halozyme Therapeutics stock has delivered a 106.2% return over the past five years, yet the current valuation checks lean toward the shares looking rich on mark...

Halozyme Therapeutics Stock Looks Expensive At Today’s Price

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.